MRK Merck and Co Inc

By Colin Kellaher

Merck & Co. (MRK) on Monday said a pivotal phase 3 study of its antibacterial product Recarbrio met its main endpoints in adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

The Kenilworth, N.J., drug maker said Recarbrio met the primary endpoint of statistical non-inferiority compared to piperacillin/tazobactam in day 28 all-cause mortality and the secondary endpoint of clinical response at early follow up in the modified intent-to-treat population.

Merck said it plans to present the full data from the trial at a scientific congress next year.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

September 30, 2019 07:24 ET (11:24 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.